source
- FDA sets May 1 decision date for uniQure's Huntington's disease gene therapy after year-long regulatory sagaThe U.S. Food and Drug Administration has accepted uniQure's biologics license application for its Huntington's disease gene therapy and placed it on the priority review track, with a May 1 target…
- Cell and gene therapy funding climbs to $2.2 billion in Q3 despite safety setbacks in CAR-T trialsSail Biomedicine’s $925 million agreement with Johnson & Johnson helped lift venture capital money into the cell and gene therapy (CGT) space during the third quarter. CGT attracted $2.2 billion a…